title: Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll.
abstract: In order to evaluate tolerance, toxicity, and in vivo antigenicity, 29 HIV-1-infected patients (eight with ARC and 21 with AIDS) were vaccinated with a synthetic peptide derived from the gp41 transmembrane protein of the HIV-1. This peptide had been coupled with 2.4 dinitrophenyl-Ficoll (F46), a T-cell independent adjuvant. The patients received a single intradeltoid injection of either 0.1 or 0.3 mg of F46. Five of the individuals with AIDS were boostered, four of them twice. Anti-F46 antibody titers were measured before vaccination, and on days 7, 14, 21, 28, 90, 180 and 270 after vaccination. Anti-F46 titers rose at least twofold over prestudy values in 10/21 individuals with AIDS and in 1/8 individuals with ARC at least once during the observation period. The overall response, however, consisted of only weak antibody production that was independent of the dose or patient characteristics. No signs of toxicity or of clinical progression related to the vaccination were observed in this phase I/II trial of a T-cell independent therapeutic vaccine.
authors.affiliation: Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106.
authors.forename: S
authors.initials: S
authors.lastname: Schwander
authors.forename: M
authors.initials: M
authors.lastname: Opravil
authors.forename: R
authors.initials: R
authors.lastname: Lüthy
authors.forename: D G
authors.initials: DG
authors.lastname: Hanson
authors.forename: J
authors.initials: J
authors.lastname: Schindler
authors.forename: A
authors.initials: A
authors.lastname: Dawson
authors.forename: B
authors.initials: B
authors.lastname: Letwin
authors.forename: M
authors.initials: M
authors.lastname: Dietrich
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D000386:AIDS-Related Complex / Q000097:blood / Q000276:immunology / Q000628:therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000628:therapy*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000941:Antigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes; D005260:Female; D005362:Ficoll / Q000031:analogs & derivatives* / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D007273:Injections, Intramuscular; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000941:Antigens; C031007:DNP-Ficoll; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D005362:Ficoll